Implitapide, a Microsomal Triglyceride Transfer Protein Inhibitor, Reduces Progression of Atherosclerosis in Apolipoprotein E Knockout Mice Fed a Western-Type Diet: Involvement of the Inhibition of Postprandial Triglyceride Elevation

• Published in: Biological & Pharmaceutical Bulletin Vol. 28; no. 2; pp. 247 - 252
• Main Authors: Ueshima, Koji, Akihisa-Umeno, Hitomi, Nagayoshi, Akira, Takakura, Shoji, Matsuo, Masahiko, Mutoh, Seitaro
• Format: Journal Article
• Language: English
• Published: Japan The Pharmaceutical Society of Japan 01.02.2005; Pharmaceutical Society of Japan
• Subjects: Animals; Aorta, Thoracic - drug effects; Aorta, Thoracic - metabolism; Apolipoproteins E - deficiency; Apolipoproteins E - genetics; Arteriosclerosis - blood; Arteriosclerosis - prevention & control; atherosclerosis; Carrier Proteins - antagonists & inhibitors; Carrier Proteins - blood; Diet, Atherogenic; Dietary Fats - administration & dosage; implitapide; Indoles - pharmacology; Indoles - therapeutic use; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; microsomal triglyceride transfer protein; Postprandial Period - drug effects; Postprandial Period - physiology; Pyridines - pharmacology; Pyridines - therapeutic use; Triglycerides - antagonists & inhibitors; Triglycerides - blood

Microsomal triglyceride transfer protein (MTP) is essential for the synthesis of both chylomicron in the intestine and very low-density lipoprotein in the liver. An MTP inhibitor, (2S)-2-cyclopentyl-2-[4-[(2,4-dimethyl-9H-pyrido[2,3-b]indol-9-yl)methyl]phenyl]-N-[(1S)-2-hydroxy-1-phenylethyl]ethanam...